ZLY025-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEZLY025Cat.No.:HY-179289CASNo.:3070379-34-6分⼦式:C₁₅H₁₃N₃O₂S分⼦量:299.35作⽤靶点:MolecularGlues;CDK;Apoptosis作⽤通路:PROTAC;CellCycle/DNADamage;Apoptosis储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性ZLY025⼀种⾼效且有⼝服活性的CCNK分⼦胶降解剂，其DC50值为42.7nM。ZLY025对多种肿瘤细胞具有⼴谱抗增殖活性，IC50值范为0.08⾄2.45μM。ZLY025可诱导细胞凋亡(apoptosis)和G1期阻滞。ZLY025可⽤于癌症研究，如肺癌。体外研究ZLY025exhibitsbroad-spectrumantiproliferativeactivityagainstvarioustumorcelllinesincludinglungcancer,breastcancer,livercancer,andleukemia,withIC50valuesrangingfrom0.08to2.45μM[1].ZLY025(125-500nM;24h)inducesA549cellsapoptosisandG1phasearrest[1].ZLY025(30-1000nM;8-24h)reducesexpressionofCCNK,CDK12,p-CTD,andBRCA1inA549cells[1].ApoptosisAnalysis[1]CellLine:A549cellsConcentration:125,250,500nMIncubationTime:24hResult:Increasedapoptosisrate.CellCycleAnalysis[1]CellLine:A549cellsConcentration:125,250,500nM1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEIncubationTime:24hResult:InducedG1phasearrest.WesternBlotAnalysis[1]CellLine:A549cellsConcentration:30,100,300,1000nMIncubationTime:8,16,24hResult:DecreasedexpressionofCCNK,CDK12,p-CTD,andBRCA1.体内研究ZLY025(10-40mg/kg;i.g.;oncedailyfor17days;)inhibitstumorgrowthinBALB/cnudemicebearingA549xenografts[1].ZLY025(200mg/kg,i.g.,oncedailyfor14days)showsextremelylowsubacutetoxicityinICRmice[1].AnimalModel:BALB/cnude(female,subcutaneousinjectionofA549humannon-smallcelllungcancer(NSCLC)cells)[1]Dosage:10,20,40mg/kgAdministration:Oralgavage;oncedailyfor17daysResult:Reducedtumorweightandvolume.Didnotaffectmousebodyweightorcausetoxicitytomajororgans.REFERENCES[1].LiuY,etal.DiscoveryofHighlyPotentandOrallyAvailableCCNKMolecularGlueDegradersasBroad-SpectrumAntitumorAgents.JMedChem.2025;68(21):22689-22714.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.T